Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008

CRANBURY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the open of the U.S. financial markets.

The Company will also conduct a conference call and live audio webcast hosted by Palatin's executive management team on November 17, 2008 at which they will discuss the results of operations in greater detail and provide an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call and Webcast

    -- Q1-Fiscal Year 2009 Financial Results
       Press Release                               11/17/2008 at 7:30 a.m. ET

    -- Q1-Fiscal Year 2009 Conference Call - Live  11/17/2008 at 11:00 a.m. ET

       Domestic Dial-In Number                     1-888-263-2919
       International Dial-In Number                1-913-312-0381
       Passcode:                                   7115648

    -- Q1-Fiscal Year 2009
       Conference Call -- Replay                   11/17-11/24/2008

       Domestic Dial-In Number                     1-888-203-1112
       International Dial-In Number                1-719-457-0820
       Replay Passcode:                            7115648

    -- Webcast Live and Replay Access              http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia-reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.